Equities

Carbiotix AB (publ)

Carbiotix AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.0732
  • Today's Change0.001 / 1.67%
  • Shares traded595.58k
  • 1 Year change-90.51%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Carbiotix AB (publ) is a Sweden-based company with operations focused on intestinal health. The Company is engaged in microbiome healthcare through a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics, alongside a range of gut health testing services. The Company’s business is conducted through four business legs: development of the prebiotic fiber Carbiotix AXOS, drug development linked to various metabolic and chronic diseases. sales of consumer and clinical tests for intestinal health and sales of medical food containing AXOS.

  • Revenue in SEK (TTM)1.47m
  • Net income in SEK-13.48m
  • Incorporated2014
  • Employees10.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lipidor AB77.00k-11.49m6.69m--------86.93-0.3964-0.39640.0027-0.32230.0084--5.31---124.54-59.41---75.10-----14,916.88-643.36--------73.33-20.3372.24------
2cureX AB155.00k-30.82m7.11m----0.5195--45.88-1.75-1.750.00880.77770.0048--0.0838---95.89-38.21-108.66-43.48-6,889.68-22,153.06-19,883.23-38,685.30---46.08----72.22---3.52------
Stayble Therapeutics AB0.00-23.74m9.83m3.00--0.5957-----0.9492-0.94920.000.52040.00----0.00-116.21-78.64-141.76-95.58------------0.049------3.22------
Amniotics AB (publ)0.00-30.87m10.66m6.00--0.6803-----0.0374-0.03740.000.00570.00----0.00-112.25-101.09-362.71-149.92--------1.12-16.17--------35.75------
Carbiotix AB (publ)1.47m-13.48m13.19m10.00--0.1918--9.00-0.302-0.3020.03240.38170.0586--2.36146,552.00-53.88-49.38-64.85-55.50235.45574.69-919.76-1,828.86---76.280.1384--259.56-12.04-10.02--13.64--
Aptahem AB32.00k-11.11m14.18m----0.1386--443.00-0.0497-0.04970.00010.22660.0005--0.0738---16.76-39.26-19.47-44.194,623.59---34,727.72-----10.170.0847-------25.36------
AegirBio AB99.00k-367.00m14.84m1.00--1.66--149.86-24.31-24.310.00470.28950.00042.000.0207---163.02---171.79---24,398.99---370,710.10--2.53-27.270.8209---87.16---292.98------
Redwood Pharma AB0.00-13.60m17.11m1.00--0.2531-----5.87-5.870.003.180.00----0.00-106.53-95.03-121.24-123.04-----------19.120.00-------8.78---5.11--
Circio Holding ASA122.32k-110.12m19.22m11.00------157.09-16.75-16.750.0181-12.890.0019--0.007211,181.82-172.29-46.58---53.40-----90,029.27-6,902.00---9.827.73---98.7735.4374.42------
Cyxone AB0.00-22.99m19.22m4.00--0.4933-----0.1902-0.19020.000.18040.00-------47.81-66.19-53.03-72.35------------0.0216------45.87---12.69--
Data as of May 03 2024. Currency figures normalised to Carbiotix AB (publ)'s reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.